MTOR and breast cancer: PD-L1 in bladder cancer (BC) facilitates mTOR signaling and autophagy, which contribute to the development of resistance to the widely employed BC chemotherapeutic drugs cisplatin and gemcitabine, as well as the mTORC1 inhibitor rapamycin [23].